Perspective

Medicine

Multiple Sclerosis
Where Does It Exactly Stem From?

Arno Hennig*
Universität Leipzig, Augustuspl. 10, 04109 Leipzig, Germany
*: All correspondence should be sent to: Dr. Arno Hennig.
Author's Contact: Arno Hennig, M.D., E-mail: ahennig1@yahoo.com
DOI: https://doi.org/10.15354/si.25.pe195
Funding: No funding source declared.
COI: The author declares no competing interest.
AI Declaration: The author affirms that artificial intelligence did not contribute to the process of preparing the work.

Multiple sclerosis (MS) is a complicated, multifaceted autoimmune disorder marked by damage to the myelin sheath of the central nervous system. The precise etiology of MS remains incompletely elucidated, though it is thought to arise from an interplay of genetic and environmental influences. Genetic predisposition contributes to the likelihood of acquiring MS, particularly in persons with a familial history of the illness. Moreover, environmental factors such as viral infections, vitamin D insufficiency, smoking, specific dietary practices, and exercise lacking have been associated with the initiation of an aberrant immune response that results in inflammation and demyelination within the central nervous system. Researchers persist in examining the complex underpinnings of MS to formulate more effective treatments and interventions for individuals impacted by this chronic neurological disorder.

Keywords: Multiple Sclerosis; Etiology; Genetics; Environmental Factors; Progression

Science Insights, January 31, 2025; Vol. 46, No. 1, pp.1705-1710.

MULTIPLE SCLEROSIS (MS) is a chronic autoimmune disease that primarily effects the brain and spinal cord of the central nervous system (Compston & Coles, 2008; Eva et al., 2023). It is distinguished by the inflammation and injury to the myelin sheath, the protective layer that envelops nerve fibers (Rolak, 2003). A variety of neurological symptoms, including fatigue, muscle weakness, and coordination and balance issues, are the result of this injury, which disrupts the communication between the brain and the rest of the body (Tsutsui & Stys, 2012). Research has provided insight into the potential factors that contribute to the development of this complex disease, despite the fact that the exact cause of MS is not yet completely understood (Correale et al., 2019; Macleod, 2016).

The development of MS is significantly influenced by genetics, as individuals who have a family history of the disease are at a higher risk of developing it themselves. Studies have identified numerous gene variations that are linked to an elevated risk of developing MS, indicating that genetic factors may be involved in the disease's development (Otaequi et al., 2013; Pytel et al., 2017). MS is also significantly influenced by environmental factors, with certain triggers, including infections,

smoking, and vitamin D deficiency, being associated with an elevated risk of developing the disease (Didonna & Oksenberg, 2017; Stoiloudis et al., 2022). The inflammation and injury observed in MS may be the result of an abnormal immune response that is triggered by the interaction of these environmental factors with genetic predisposition (Barrie et al., 2024; Munger & Ascherio, 2007).

A malfunctioning immune system is one of the primary factors that are believed to contribute to the development of MS. The immune system mistakenly assaults the myelin sheath in individuals with MS, resulting in inflammation and damage to the nerve fibers (Ortíz et al., 2013; Rolak, 2003). Although the precise mechanisms involved are still not fully understood, it is believed that this abnormal immune response is the result of a combination of genetic and environmental factors. Research has demonstrated that the development of MS is significantly influenced by specific immune cells, including T cells and B cells (Høglund & Maghazachi, 2014; Ortíz et al., 2013). Abnormalities in these cells are associated with the disease. The identification of particular immune cells that specifically target the myelin sheath in individuals with MS has provided additional insight into the underlying mechanisms of the disease (Dargahi et al., 2017; Ifergan & Miller, 2020). T cells, which are immune cells, are activated by environmental triggers, such as viral infections, and migrate to the central nervous system, where they target the myelin sheath (Barrie et al., 2024; Martin et al., 1992). MS is characterized by the formation of scar tissue, or lesions, in the brain and spinal cord as a result of this immune response (Ifergan & Miller, 2020; Hemmer et al., 2004).

Vitamin D deficiency is an additional environmental factor that has been linked to MS. Research has demonstrated that individuals residing in regions with reduced sunlight exposure, and as a result, lesser levels of vitamin D, are at an increased risk of developing MS (Hayes & Acheson, 2008; Koch et al., 2012). The function that Vitamin D plays in modulating the immune system is one potential explanation for the relationship between MS and Vitamin D deficiency (Hayes & Acheson, 2008; Ortíz et al., 2013). The immune response is regulated by vitamin D, and a deficiency in this vitamin may result in an overactive immune system that attacks the body's own tissues, thereby contributing to the development of MS (Bishop et al., 2020; Hayes & Acheson, 2008). Furthermore, Vitamin D has been demonstrated to possess anti-inflammatory properties, which may aid in the mitigation of inflammation in the central nervous system, a critical component of MS (Pierrot-Deseilligny, 2009; Pierrot-Deseilligny & Souberbielle, 2017). A correlation between low levels of Vitamin D and an elevated risk of developing MS has been demonstrated. For instance, individuals with elevated levels of Vitamin D had a reduced risk of developing MS in comparison to those with lower levels of the vitamin (Smolders et al., 2008). This implies that it may be crucial to maintain sufficient Vitamin D levels in order to prevent the onset of MS.

The function of the gut microbiome in the development of MS has also been the subject of recent research (Ascherio, 2013). Changes in the composition of gut bacteria have been associated with autoimmune diseases, such as MS, and the gut microbiome is essential for immune system regulation (Cekanaviciute et al., 2017; Ochoa-Repáraz et al., 2018). It is hypothesized that certain types of bacteria may induce an aberrant immune response in individuals with a genetic predisposition to the disease, resulting in the development of MS (Shahi et al., 2017). Additionally, modifications to the gastrointestinal microbiome have been associated with the progression and severity of MS in individuals (Libbey et al., 2013; Schepici et al., 2019). Research has demonstrated that individuals with the most diverse intestinal bacteria exhibit milder symptoms and lower disease activity than those with the least diverse microbiomes (Ascherio, 2013; Jangi et al., 2016). This implies that the gastrointestinal microbiome may serve as a potential target for the development of novel therapies for MS.

Furthermore, studies showed that other factors, such as viral infections and lifestyle choices, may also contribute to the development of MS (Chen et al., 2016; Schepici et al., 2019; Shahi et al., 2017). It has been hypothesized in certain studies that certain viral infections, such as Epstein-Barr virus (EBV), may induce an abnormal immune response that results in the development of MS (Fernández et al., 2011; Munger & Ascherio, 2007; Ortíz et al., 2013). Exposure to specific viruses, including the EBV, is one of the primary environmental factors that has been associated with MS (Haahr & Höllsberg, 2006). EBV is a prevalent virus that infects the majority of the population at some point in their lives (DeLorenze et al., 2006). However, in certain individuals, it may induce an anomalous immune response that results in the development of MS (Laurence & Benito-León, 2017; Libbey et al., 2013). In addition, the herpes virus and the human endogenous retrovirus have been implicated in the development of MS (Virtanen & Jacobson, 2012).

The risk of developing the disease has also been linked to lifestyle choices, including smoking and a lack of physical activity. Genetic and immune system factors may interact with these factors to elevate the probability of developing MS (Munger & Ascherio, 2007). Smoking is one lifestyle factor that has been associated with an elevated risk of developing MS. Research has demonstrated that tobacco smoke contains toxins that have the potential to induce an inflammatory response in the body, which may result in the development of autoimmune conditions such as MS (Janssen et al., 2024; Katukuri et al., 2020; Mandia et al., 2014). Furthermore, smoking has been demonstrated to exacerbate symptoms in individuals who have already been diagnosed with MS, rendering it a critical risk factor to take into account for the prevention and management of the disease (Weston & Constantinescu, 2015). Diet is an additional lifestyle decision that may impact the progression of MS (Jakimovski et al., 2019). According to research, a diet that is deficient in fruits and vegetables and is high in saturated fats may be linked to an elevated risk of developing MS, whereas a diet that is abundant in omega-3 fatty acids and antioxidants may have a protective factor (Goldberg, 1974; Mazzucca et al., 2024; Stoiloudis et al., 2022). In addition, it has been demonstrated that individuals with MS can enhance their quality of life and delay the progression of the disease by maintaining a healthy weight and participating in regular physical activity (Hadgkiss et al., 2014; Jakimovski et al., 2019).

The absence of definitive tests for the disease and the variability of symptoms frequently make the diagnosis of MS a

difficult task (Roos, 2017). Nevertheless, the capacity to diagnose and monitor MS has been significantly enhanced by advancements in imaging techniques, such as MRI scans (Joy & Johnston, 2001; Waldman et al., 2014). The treatment options for MS are centered on the prevention of relapses, the management of symptoms, and the halting of disease progression (Zivadinov, 2015). Lifestyle modifications, physical therapy, and medications are frequently implemented to alleviate symptoms and enhance the quality of life for individuals with MS (Khan et al., 2011; Nouh et al., 2024).

Our comprehension of this intricate illness is being furthered by ongoing research into the underlying causes of MS. As well as potential targets for novel therapies, recent research has identified potential biomarkers that may assist in the prediction of disease progression and response to treatment (Cai & Huang, 2018; Harris & Sadiq, 2014). While the precise cause of MS remains enigmatic, ongoing research is elucidating the intricate interplay between genetics, immune function, and environmental factors that contribute to the disease's development (Didonna & Oksenberg, 2015; Gourraud et al., 2012; Weinshenker, 1994).

In sum, MS is a multifaceted autoimmune disorder that impacts the central nervous system. Although the precise cause of MS remains unknown, research has identified genetic, immune system, environmental, and lifestyle factors that contribute to the disease's development. The care and management of MS have been significantly enhanced by advancements in imaging techniques and treatment options; however, additional research is required to gain a comprehensive understanding of the underlying mechanisms. We can anticipate the development of novel strategies for the prevention and treatment of this difficult disease by continuing to investigate the genetics, immune function, and environmental triggers of MS.■

Received: November 21, 2024 | Revised: December 19, 2024 | Accepted: December 29, 2024

References

Ascherio, A. (2013). Environmental factors in multiple sclerosis. Expert Review of Neurotherapeutics, 13(sup2), 3–9. DOI: https://doi.org/10.1586/14737175.2013.865866

Barrie, W., Yang, Y., Irving-Pease, E. K., Attfield, K. E., Scorrano, G., Jensen, L. T., Armen, A. P., Dimopoulos, E. A., Stern, A., Refoyo-Martinez, A., Pearson, A., Ramsøe, A., Gaunitz, C., Demeter, F., Jørkov, M. L. S., Møller, S. B., Springborg, B., Klassen, L., Hyldgård, I. M., . . . Willerslev, E. (2024). Elevated genetic risk for multiple sclerosis emerged in steppe pastoralist populations. Nature, 625(7994), 321–328. DOI: https://doi.org/10.1038/s41586-023-06618-z

Bishop, E. L., Ismailova, A., Dimeloe, S., Hewison, M., & White, J. H. (2020). Vitamin D and immune regulation: Antibacterial, Antiviral, Anti‐Inflammatory. JBMR Plus, 5(1). DOI: https://doi.org/10.1002/jbm4.10405

Cai, L., & Huang, J. (2018). Neurofilament light chain as a biological marker for multiple sclerosis: a meta-analysis study. Neuropsychiatric Disease and Treatment, Volume 14, 2241–2254. DOI: https://doi.org/10.2147/ndt.s173280

Cekanaviciute, E., Yoo, B. B., Runia, T. F., Debelius, J. W., Singh, S., Nelson, C. A., Kanner, R., Bencosme, Y., Lee, Y. K., Hauser, S. L., Crabtree-Hartman, E., Sand, I. K., Gacias, M., Zhu, Y., Casaccia, P., Cree, B. a. C., Knight, R., Mazmanian, S. K., & Baranzini, S. E. (2017). Gut bacteria from multiple sclerosis patients modulate human T cells and exacerbate symptoms in mouse models. Proceedings of the National Academy of Sciences, 114(40), 10713–10718. DOI: https://doi.org/10.1073/pnas.1711235114

Chen, J., Chia, N., Kalari, K. R., Yao, J. Z., Novotna, M., Soldan, M. M. P., Luckey, D. H., Marietta, E. V., Jeraldo, P. R., Chen, X., Weinshenker, B. G., Rodriguez, M., Kantarci, O. H., Nelson, H., Murray, J. A., & Mangalam, A. K. (2016). Multiple sclerosis patients have a distinct gut microbiota compared to healthy controls. Scientific Reports, 6(1). DOI: https://doi.org/10.1038/srep28484

Compston, A., & Coles, A. (2008). Multiple sclerosis. The Lancet, 372(9648), 1502–1517. DOI: https://doi.org/10.1016/s0140-6736(08)61620-7

Correale, J., Marrodan, M., & Ysrraelit, M. C. (2019). Mechanisms of neurodegeneration and axonal dysfunction in progressive multiple sclerosis. Biomedicines, 7(1), 14. DOI: https://doi.org/10.3390/biomedicines7010014

Dargahi, N., Katsara, M., Tselios, T., Androutsou, M., De Courten, M., Matsoukas, J., & Apostolopoulos, V. (2017). Multiple sclerosis: Immunopathology and treatment update. Brain Sciences, 7(7), 78. DOI: https://doi.org/10.3390/brainsci7070078

DeLorenze, G. N., Munger, K. L., Lennette, E. T., Orentreich, N., Vogelman, J. H., & Ascherio, A. (2006). Epstein-Barr virus and multiple sclerosis. Archives of Neurology, 63(6), 839. DOI: https://doi.org/10.1001/archneur.63.6.noc50328

Didonna, A., & Oksenberg, J. R. (2015). Genetic determinants of risk and progression in multiple sclerosis. Clinica Chimica Acta, 449, 16–22. DOI: https://doi.org/10.1016/j.cca.2015.01.034

Didonna, A., & Oksenberg, J. R. (2017). The genetics of multiple sclerosis. In Codon Publications eBooks (pp. 3–16). DOI: https://doi.org/10.15586/codon.multiplesclerosis.2017.ch1

Eva, L., Pleș, H., Covache-Busuioc, R., Glavan, L. A., Bratu, B., Bordeianu, A., Dumitrascu, D., Corlatescu, A. D., & Ciurea, A. V. (2023). A Comprehensive Review on Neuroimmunology: Insights from Multiple Sclerosis to Future Therapeutic Developments. Biomedicines, 11(9), 2489. DOI: https://doi.org/10.3390/biomedicines11092489

Fernandez, A. M., Papais-Alvarenga, M., Fernandez, V., Guerrero, M., & Fernandez, O. (2011). Microbes, immunity and multiple sclerosis. Current Immunology Reviews, 7(1), 75–82. DOI: https://doi.org/10.2174/157339511794474262

Goldberg, P. (1974a). Multiple sclerosis: vitamin D and calcium as environmental determinants of prevalence. International Journal of Environmental Studies, 6(1), 19–27. DOI: https://doi.org/10.1080/00207237408709630

Goldberg, P. (1974b). Multiple sclerosis: vitamin D and calcium as environmental determinants of prevalence. International Journal of Environmental Studies, 6(1), 19–27. DOI: https://doi.org/10.1080/00207237408709630

Gourraud, P., Harbo, H. F., Hauser, S. L., & Baranzini, S. E. (2012). The genetics of multiple sclerosis: an up-to-date review. Immunological Reviews, 248(1), 87-103. DOI: https://doi.org/10.1111/j.1600-065x.2012.01134.x

Haahr, S., & Höllsberg, P. (2006). Multiple sclerosis is linked to Epstein-Barr virus infection. Reviews in Medical Virology, 16(5), 297‐310. DOI: https://doi.org/10.1002/rmv.503

Hadgkiss, E. J., Jelinek, G. A., Weiland, T. J., Pereira, N. G., Marck, C. H., & Van Der Meer, D. M. (2014). The association of diet with quality of life, disability, and relapse rate in an international sample of people with multiple sclerosis. Nutritional Neuroscience, 18(3), 125–136. DOI: https://doi.org/10.1179/1476830514y.0000000117

Harris, V. K., & Sadiq, S. A. (2014). Biomarkers of Therapeutic Response in Multiple sclerosis: current status. Molecular Diagnosis & Therapy, 18(6), 605–617. DOI: https://doi.org/10.1007/s40291-014-0117-0

Hayes, C. E., & Acheson, E. D. (2008). A unifying multiple sclerosis etiology linking virus infection, sunlight, and vitamin D, through viral interleukin-10. Medical Hypotheses, 71(1), 85–90. DOI: https://doi.org/10.1016/j.mehy.2008.01.031

Hemmer, B., Cepok, S., Zhou, D., & Sommer, N. (2004). Multiple sclerosis - a coordinated immune attack across the blood brain barrier. Current Neurovascular Research, 1(2), 141–150. DOI: https://doi.org/10.2174/1567202043480152

Høglund, R. A., & Maghazachi, A. (2014). Multiple sclerosis and the

role of immune cells. World Journal of Experimental Medicine, 4(3), 27. DOI: https://doi.org/10.5493/wjem.v4.i3.27

Ifergan, I., & Miller, S. D. (2020). Potential for targeting myeloid cells in controlling CNS inflammation. Frontiers in Immunology, 11. DOI: https://doi.org/10.3389/fimmu.2020.571897

Jakimovski, D., Guan, Y., Ramanathan, M., Weinstock-Guttman, B., & Zivadinov, R. (2019). Lifestyle-based modifiable risk factors in multiple sclerosis: Review of experimental and clinical findings. Neurodegenerative Disease Management, 9(3), 149–172. DOI: https://doi.org/10.2217/nmt-2018-0046

Jangi, S., Gandhi, R., Cox, L. M., Li, N., Von Glehn, F., Yan, R., Patel, B., Mazzola, M. A., Liu, S., Glanz, B. L., Cook, S., Tankou, S., Stuart, F., Melo, K., Nejad, P., Smith, K., Topçuolu, B. D., Holden, J., Kivisäkk, P., . . . Weiner, H. L. (2016). Alterations of the human gut microbiome in multiple sclerosis. Nature Communications, 7(1). DOI: https://doi.org/10.1038/ncomms12015

Janssen, F., Braun, M., Dröge, J., Brüggmann, D., & Groneberg, D. A. (2024). Comparison between smoked tobacco and medical cannabis cigarettes concerning particulate matter. Cannabis and Cannabinoid Research. DOI: https://doi.org/10.1089/can.2023.0201

Joy, J. E., & Johnston, R. B., Jr. (2001). Characteristics and management of major symptoms. Multiple Sclerosis - NCBI Bookshelf. https://www.ncbi.nlm.nih.gov/books/NBK222388/

Khan, F., Amatya, B., & Turner-Stokes, L. (2011). Symptomatic therapy and rehabilitation in primary progressive multiple sclerosis. Neurology Research International, 2011, 1–22. DOI: https://doi.org/10.1155/2011/740505

Koch, M. W., Metz, L. M., Agrawal, S. M., & Yong, V. W. (2012). Environmental factors and their regulation of immunity in multiple sclerosis. Journal of the Neurological Sciences, 324(1–2), 10–16. DOI: https://doi.org/10.1016/j.jns.2012.10.021

Laurence, M., & Benito-León, J. (2017). Epstein–Barr virus and multiple sclerosis: Updating Pender's hypothesis. Multiple Sclerosis and Related Disorders, 16, 8–14. DOI: https://doi.org/10.1016/j.msard.2017.05.009

Libbey, J. E., Cusick, M. F., & Fujinami, R. S. (2013). Role of pathogens in multiple sclerosis. International Reviews of Immunology, 33(4), 266–283. DOI: https://doi.org/10.3109/08830185.2013.823422

Macleod, G. (2016). Understanding multiple sclerosis by examination of theories in medical literature. MOJ Cell Science & Report, 3(5). DOI: https://doi.org/10.15406/mojcsr.2016.03.00072

Mandia, D., Ferraro, O., Nosari, G., Montomoli, C., Zardini, E., & Bergamaschi, R. (2014). Environmental Factors and multiple sclerosis severity: A Descriptive study. International Journal of Environmental Research and Public Health, 11(6), 6417–6432. DOI: https://doi.org/10.3390/ijerph110606417

Martin, R., McFarland, H. F., & McFarlin, D. E. (1992). Immunological aspects of demyelinating diseases. Annual Review of Immunology, 10(1), 153–187. DOI: https://doi.org/10.1146/annurev.iy.10.040192.001101

Mazzucca, C. B., Scotti, L., Comi, C., Vecchio, D., Chiocchetti, A., & Cappellano, G. (2024). The role of diet in multiple sclerosis onset: A prospective study using UK Biobank. Nutrients, 16(11), 1746. DOI: https://doi.org/10.3390/nu16111746

Munger, K. L., & Ascherio, A. (2007). Risk factors in the development of multiple sclerosis. Expert Review of Clinical Immunology, 3(5), 739–748. DOI: https://doi.org/10.1586/1744666x.3.5.739

Nishanth, K., Tariq, E., Nzvere, F. P., Miqdad, M., & Cancarevic, I. (2020). Role of smoking in the pathogenesis of multiple sclerosis: a review article. Cureus. DOI: https://doi.org/10.7759/cureus.9564

Nouh, R. A., Kamal, A., Oyewole, O., Abbas, W. A., Abib, B., Omar, A., Mansour, S. T., & Abdelnaser, A. (2024). Unveiling the potential of cannabinoids in multiple sclerosis and the dawn of Nano-Cannabinoid medicine. Pharmaceutics, 16(2), 241. DOI: https://doi.org/10.3390/pharmaceutics16020241

Ochoa-Repáraz, J., Kirby, T. O., & Kasper, L. H. (2018). The gut microbiome and multiple sclerosis. Cold Spring Harbor Perspectives in Medicine, 8(6), a029017. DOI: https://doi.org/10.1101/cshperspect.a029017

Ortiz, G. G., Pacheco-Moisés, F. P., Bitzer-Quintero, O. K., Ramírez-Anguiano, A. C., Flores-Alvarado, L. J., Ramírez-Ramírez, V., Macias-Islas, M. A., & Torres-Sánchez, E. D. (2013). Immunology and oxidative stress in multiple sclerosis: Clinical and Basic approach. Clinical and Developmental Immunology, 2013, 1–14. DOI: https://doi.org/10.1155/2013/708659

Otaequi, D., Muñoz-Culla, N., & Irizar, N. (2013). The genetics of multiple sclerosis: review of current and emerging candidates. The Application of Clinical Genetics, 63. DOI: https://doi.org/10.2147/tacg.s29107

Pierrot-Deseilligny, C. (2009). Clinical implications of a possible role of vitamin D in multiple sclerosis. Journal of Neurology, 256(9), 1468–1479. DOI: https://doi.org/10.1007/s00415-009-5139-x

Pierrot-Deseilligny, C., & Souberbielle, J. (2017). Vitamin D and multiple sclerosis: An update. Multiple Sclerosis and Related Disorders, 14, 35–45. DOI: https://doi.org/10.1016/j.msard.2017.03.014

Pytel, V., Matías-Guiu, J. A., Torre-Fuentes, L., Montero, P., Gómez-Graña, Á., García-Ramos, R., Moreno-Ramos, T., Oreja-Guevara, C., Fernández-Arquero, M., Gómez-Pinedo, U., & Matías-Guiu, J. (2017). Familial multiple sclerosis and association with other autoimmune diseases. Brain and Behavior, 8(1). DOI: https://doi.org/10.1002/brb3.899

Rolak, L. A. (2003). Multiple sclerosis: it's not the disease you thought it was. Clinical Medicine & Research, 1(1), 57–60. DOI: https://doi.org/10.3121/cmr.1.1.57

Roos, J. (2017). Combination aquatic and land physical therapy

program improved function and reduced spasticity after acute illness and exacerbation of multiple sclerosis: A case report. Physical Medicine and Rehabilitation Research, 1(4). DOI: https://doi.org/10.15761/pmrr.1000118

Schepici, G., Silvestro, S., Bramanti, P., & Mazzon, E. (2019). The gut microbiota in multiple sclerosis: An overview of clinical trials. Cell Transplantation, 28(12), 1507–1527. DOI: https://doi.org/10.1177/0963689719873890

Shahi, S. K., Freedman, S. N., & Mangalam, A. K. (2017). Gut microbiome in multiple sclerosis: The players involved and the roles they play. Gut Microbes, 8(6), 607–615. DOI: https://doi.org/10.1080/19490976.2017.1349041

Smolders, J., Damoiseaux, J., Menheere, P., & Hupperts, R. (2008). Vitamin D as an immune modulator in multiple sclerosis, a review. Journal of Neuroimmunology, 194(1–2), 7–17. DOI: https://doi.org/10.1016/j.jneuroim.2007.11.014

Stoiloudis, P., Kesidou, E., Bakirtzis, C., Sintila, S., Konstantinidou, N., Boziki, M., & Grigoriadis, N. (2022). The Role of Diet and Interventions on Multiple Sclerosis: A review. Nutrients, 14(6), 1150. DOI: https://doi.org/10.3390/nu14061150

Tsutsui, S., & Stys, P. K. (2012). Metabolic injury to axons and myelin. Experimental Neurology, 246, 26–34. DOI: https://doi.org/10.1016/j.expneurol.2012.04.016

Virtanen, J. O., & Jacobson, S. (2012). Viruses and multiple sclerosis. CNS & Neurological Disorders - Drug Targets, 11(5), 528–544. DOI: https://doi.org/10.2174/187152712801661220

Waldman, A., Ghezzi, A., Bar-Or, A., Mikaeloff, Y., Tardieu, M., & Banwell, B. (2014). Multiple sclerosis in children: an update on clinical diagnosis, therapeutic strategies, and research. The Lancet Neurology, 13(9), 936–948. DOI: https://doi.org/10.1016/s1474-4422(14)70093-6

Weinshenker, B. G. (1994). Natural history of multiple sclerosis. Annals of Neurology, 36(S1), S6–S11. DOI: https://doi.org/10.1002/ana.410360704

Weston, M., & Constantinescu, C. S. (2015). What role does tobacco smoking play in multiple sclerosis disability and mortality? A review of the evidence. Neurodegenerative Disease Management, 5(1), 19–25. DOI: https://doi.org/10.2217/nmt.14.45

Zivadinov, R. (2015). Role of neuroimaging in multiple sclerosis. In Elsevier eBooks (pp. 443–478). DOI: https://doi.org/10.1016/b978-0-12-800763-1.00018-x